참고문헌
- Ogle OE. Excision of sublingual gland. Oral Maxillofac Surg Clin North Am. 2021;33:161-168. https://doi.org/10.1016/j.coms.2020.12.001
- Chung YS, Cho Y, Kim BH. Comparison of outcomes of treatment for ranula: a proportion meta-analysis. Br J Oral Maxillofac Surg. 2019;57:620-626. https://doi.org/10.1016/j.bjoms.2019.06.005
- Roh JL. Transoral Complete vs Partial Excision of the Sublingual Gland for Plunging Ranula. Otolaryngol Head Neck Surg. 2022;167:479-483. https://doi.org/10.1177/01945998211067500
- Kono M, Satomi T, Abukawa H, Hasegawa O, Watanabe M, Chikazu D. Evaluation of OK-432 Injection Therapy as Possible Primary Treatment of Intraoral Ranula. J Oral Maxillofac Surg. 2017;75:336-342. https://doi.org/10.1016/j.joms.2016.08.013
- Ogita S, Tsuto T, Nakamura K, Deguchi E, Tokiwa K, Iwai N. OK-432 therapy for lymphangioma in children: why and how does it work? J Pediatr Surg. 1996;31:477-480. https://doi.org/10.1016/S0022-3468(96)90478-9
- Ogita S, Tsuto T, Tokiwa K, Takahashi T. Treatment of cystic hygroma in children with special reference to OK-432 therapy. Z Kinderchir. 1987;42:279-281. https://doi.org/10.1055/s-2008-1075602
- Patel MR, Deal AM, Shockley WW. Oral and plunging ranulas: What is the most effective treatment? Laryngoscope. 2009;119:1501-1509. https://doi.org/10.1002/lary.20291
- Hayashi Y, Torisu M. New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils. Surgery. 1990;107:74-84.
- Ohta N, Fukase S, Suzuki Y, Ishida A, Aoyagi M. Treatments of various otolaryngological cystic diseases by OK-4321: its indications and limitations. Laryngoscope. 2010;120:2193-2196. https://doi.org/10.1002/lary.21141
- Roh JL, Kim HS. Primary treatment of pediatric plunging ranula with nonsurgical sclerotherapy using OK-432 (Picibanil). Int J Pediatr Otorhinolaryngol. 2008;72:1405-1410. https://doi.org/10.1016/j.ijporl.2008.06.003